Faron Pharmaceuticals Oy

AIM:FARN Stock Report

Market Cap: UK£185.7m

Faron Pharmaceuticals Oy Past Earnings Performance

Past criteria checks 0/6

Faron Pharmaceuticals Oy's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 105.5% per year.

Key information

-20.1%

Earnings growth rate

-7.4%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-105.5%
Return on equity-2,292.2%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Aug 02
Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

Mar 05
Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Nov 20
What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Revenue & Expenses Breakdown

How Faron Pharmaceuticals Oy makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:FARN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-32918
31 Mar 240-31919
31 Dec 230-31920
30 Sep 230-30919
30 Jun 230-29819
31 Mar 230-29820
31 Dec 220-29821
30 Sep 220-26920
30 Jun 220-241118
31 Mar 220-221018
31 Dec 210-211017
30 Sep 210-21817
30 Jun 210-20517
31 Mar 210-19516
31 Dec 200-17514
30 Sep 200-16412
30 Jun 200-14411
31 Mar 200-14411
31 Dec 190-13310
30 Sep 190-13310
30 Jun 190-12310
31 Mar 190-16313
31 Dec 180-20416
30 Sep 181-24421
30 Jun 181-28425
31 Mar 181-25322
31 Dec 171-21319
30 Sep 172-17315
30 Jun 172-14311
31 Mar 172-12310
31 Dec 162-1029
30 Sep 160-938
30 Jun 160-736
31 Mar 161-735
31 Dec 151-634
30 Sep 151-523
30 Jun 151-312
31 Mar 151-212
31 Dec 141-101
31 Dec 130-202

Quality Earnings: FARN is currently unprofitable.

Growing Profit Margin: FARN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FARN is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare FARN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FARN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16%).


Return on Equity

High ROE: FARN has a negative Return on Equity (-2292.17%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies